- SYNTHESE ORGANOMETALLIQUE D'α-AMINOESTERS N,N-DISUBSTITUES
-
Reaction of organozinc compounds with a particular gem-aminoether ester, i.e. methyl-N,N-diethylamino methoxyacetate, leads to α-aminoesters.This method allows the synthesis of compounds having potential biological activity, viz. β-unsaturated α-aminoesters.
- Bourhis, Mireille,Bosc, Jean-Jacques,Golse, Rene
-
-
Read Online
- Synthesis of B-ring-fluorinated (?)-epicatechin gallate derivatives
-
The synthesis of enantiomerically pure B-ring fluorinated catechin derivatives is presented. In a convergent approach the chromane was obtained by reaction of a lithiated fluoro-resorcine with an optically active epoxide. The latter was prepared from 3,4-
- Baumgarten, Kai D.,Czekelius, Constantin,Michaelis, Carina S.,Thieltges, David D. S.
-
supporting information
p. 4024 - 4028
(2020/06/09)
-
- Decarboxylative Negishi Coupling of Redox-Active Aliphatic Esters by Cobalt Catalysis
-
A cobalt-catalyzed decarboxylative Negishi coupling reaction of redox-active aliphatic esters with organozinc reagents was developed. The method enabled efficient alkyl–aryl, alkyl–alkenyl, and alkyl–alkynyl coupling reactions under mild reaction conditions with no external ligand or additive needed. The success of an in situ activation protocol and the facile synthesis of the drug molecule (±)-preclamol highlight the synthetic potential of this method. Mechanistic studies indicated that a radical mechanism is involved.
- Liu, Xu-Ge,Zhou, Chu-Jun,Lin,Han, Xiang-Lei,Zhang, Shang-Shi,Li, Qingjiang,Wang, Honggen
-
supporting information
p. 13096 - 13100
(2018/09/21)
-
- Process Research and Development of an Enantiomerically Enriched Allyic Amine, One of the Key Intermediates for the Manufacture of Synthetic Tetracyclines
-
A robust, cost-effective, and high yielding manufacturing process for enantiomerically enriched (S)-allylic amine 3, a key intermediate for fully synthetic tetracyclines have been developed. Two novel and scalable asymmetric vinylations resulting in high-to-excellent stereoselectivity have been developed for the key step. The final product is purified by an efficient crystallization of a l-tartaric salt. The process described has been used to manufacture ~350 kg of the tartaric salt of 3 with 99.0% ee in 8 steps (35% overall yield) from cheap and readily available dimethyl maleate.
- Zhang, Wu-Yan,Hogan, Philip C.,Chen, Chi-Li,Niu, John,Wang, Zhimin,Lafrance, Danny,Gilicky, Olga,Dunwoody, Nicholas,Ronn, Magnus
-
p. 1784 - 1795
(2015/12/01)
-
- Nickel-catalyzed multicomponent coupling of alkyne, buta-1,3-diene, and dimethylzinc under carbon dioxide
-
A nickel catalyst promoted the coupling of alkynes with buta-1,3-diene and dimethylzinc under carbon dioxide to provide (5E,8Z)-2-vinyldeca-5,8-dienoic acids with high regio- and stereo selectivity. Georg Thieme Verlag Stuttgart. New York.
- Mori, Yasuyuki,Mori, Takamichi,Onodera, Gen,Kimura, Masanari
-
supporting information
p. 2287 - 2292
(2014/11/26)
-
- Model studies for a ring-closing metathesis approach to the bafilomycin macrolactone core from a 2,2-Dimethoxy tetraenic ester precursor
-
A ring-closing metathesis strategy is reported for the construction of the 16-membered macrolactone core of the bafilomycins. One decisive key feature is the presence of a 2,2-dimethoxyketal functionality at C-2 that provides the required flexibility to the tetraenic ester precursor, allowing the ring-closing metathesis reaction to take place. Three different model esters of increasing complexity were successfully subjected to the 1,3-diene-ene ring-closing metathesis reaction. The best promoter for the simplest esters was the Grubbs first-generation precatalyst. A Hoveyda-Grubbs-type trifluoromethylamido- containing precatalyst developed by Mauduit's group gave satisfactory results for the most complex ester. In all experiments, the 12-Z-configured isomer was obtained as the major product. Subsequent microwave-promoted methanol elimination was achieved on the simplest model compound using camphorsulfonic acid (CSA) as a catalyst. Under these conditions, a E to Z isomerization of the double bond at C-4, as well as ca. 50 % isomerization of the 12-Z double bond into the corresponding 12-E isomer, were observed. Thanks to the presence of a 2,2-dimethoxyketal functionality at C-2 of the ester precursors, models of the bafilomycin core were synthesized using a ring-closing metathesis strategy. An indenylidene Ru complex gave the best results for the ring-closing metathesis step on an advanced model ester. Finally, acid-catalysed elimination of MeOH yielded the required tetraenic macrolactone. Copyright
- Chevalley, Alice,Prunet, Joelle,Mauduit, Marc,Ferezou, Jean-Pierre
-
p. 8265 - 8278
(2014/01/06)
-
- SYNTHESIS OF ENONE INTERMEDIATE
-
The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The recent development of a modular synthesis of tetracycline analogs through a chiral enone intermediate has allowed for the efficient synthesis of novel tetracycline analogs never prepared before. The present invention provides a more efficient route for preparing the enone intermediate.
- -
-
Page/Page column 76
(2008/12/08)
-
- MIGRASTATIN ANALOGS IN THE TREATMENT OF CANCER
-
In one aspect, the present invention provides a method for treating colon and/or ovarian cancer in a subject comprising administering to a subject in need thereof a compound of general formula (I): wherein R1-R6, R, ,-R,, Q, Y1, Y2 and n are as defined herein, wherein the compound is present in an amount effective to inhibit colon and/or ovarian tumor metastasis.
- -
-
Page/Page column 165
(2008/06/13)
-
- MIGRASTATIN ANALOG COMPOSITIONS AND USES THEREOF
-
In one aspect, the present invention provides pharmaceutical compositions comprising a therapeutically effective amount of a compound of general formula (I), wherein R1-R6, Ra-RC, Q, Y1, Y2 and n are as defined herein, whereby the composition is formulated for administration to a subject at a dosage between about 0.1 mg/kg to about 50 mg/kg of body weight. In another aspect, the present invention provides a method for treating breast tumor metastasis in a subject comprising administering to a subject in need thereof a therapeutically effective amount of the inventive composition described directly above and a pharmaceutically acceptable carrier, adjuvant or vehicle.
- -
-
Page 169-170
(2010/02/08)
-